Get the Stockscreener App
17.84
1.77%
0.31
Pre-market:
17.80
-0.04
-0.22%
Corvus Pharmaceuticals Inc stock is traded at $17.84, with a volume of 883.69K.
It is up +1.77% in the last 24 hours and down -14.31% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$17.53
Open:
$17.52
24h Volume:
883.69K
Relative Volume:
0.27
Market Cap:
$1.49B
Revenue:
-
Net Income/Loss:
$-15.08M
P/E Ratio:
-33.36
EPS:
-0.5348
Net Cash Flow:
$-32.22M
1W Performance:
-1.98%
1M Performance:
-14.31%
6M Performance:
+211.34%
1Y Performance:
+346.00%
1-Day Range:
$17.08
$17.99
1-Week Range:
$16.84
$18.73
52-Week Range:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
17.84 | 1.47B | 0 | -15.08M | -32.22M | -0.5348 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Market Recap: Is Corvus Pharmaceuticals Inc stock forming a cup and handle2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data - Sahm
Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 - MarketBeat
Corvus Pharmaceuticals at Oppenheimer: Soquelitinib’s Promising Potential By Investing.com - Investing.com Canada
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Yahoo Finance
Corvus Pharma sets virtual Oppenheimer talk, 90-day replay - Stock Titan
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6%Time to Sell? - MarketBeat
Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm
Is Corvus Pharmaceuticals (CRVS) Still Attractive After A 185% Monthly Surge? - simplywall.st
Corvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70 - MSN
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - Investing.com
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - The Globe and Mail
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum - Sahm
Mizuho Raises Price Target on Corvus Pharmaceuticals to $30 From $20, Keeps Outperform Rating - marketscreener.com
Corvus Soquelitinib Data Spurs Phase 2 Plans And Fuels CRVS Reassessment - Sahm
Aug Selloffs: Why is Corvus Pharmaceuticals Inc. stock going downJuly 2025 Price Swings & Accurate Entry/Exit Alerts - mfd.ru
Will Corvus Pharmaceuticals Inc. benefit from rate cutsPrice Action & Low Risk Growth Stock Ideas - mfd.ru
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet - Your Wyoming Link
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know - Yahoo Finance
10 Big Names Stumbling Hard - Insider Monkey
Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump - Finviz
Latham Watkins Advises Corvus Pharmaceuticals in Upsized Public Offering of Common Stock - Latham & Watkins LLP
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3%Here's What Happened - MarketBeat
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc exposed to political risk2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study - Finviz
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance
Corvus Pharmaceuticals (CRVS) Valuation Check After Positive Soquelitinib Data And Equity Raise - Sahm
What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc? - Sahm
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - The Manila Times
Corvus Pharmaceuticals raises $201.2 million in upsized public offering By Investing.com - Investing.com South Africa
Corvus rally continues as clinical optimism offsets dilution concerns - Mugglehead Investment Magazine
Corvus Pharmaceuticals raises $201.2 million in upsized public offering - Investing.com
Corvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 Million - Quiver Quantitative
Corvus Pharma raises $201M to support cancer and skin trials - stocktitan.net
Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock By Investing.com - Investing.com Canada
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Announces Public Offering of Common Stock - TradingView
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies - TipRanks
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):